
ISP WIV

MEACB 2017





Scientific Programme

Thursday, 23th November 2017

10:15	Welcome (Dr. D. Breyer, Head <i>a.i.</i> SBB)		
10:30	SESSION I : Evidence-based risk management		
	Prof. P. Van Damme (University of Antwerp, Belgium)	The conduct of a vaccine study with a novel live attenuated polio vaccine, under containment.	
	Dr. N. Willemarck (Scientific Institute of Public Health, Belgium)	Evidence-based biosafety.	
	Dr. S. Strassheim (ZKBS, Germany)	Environmental risk assessment of GMO medicinal products – New procedures, new challenges?	
	Session discussion		
12:30	Lunch		
14:00	SESSION II: High-throughput technologies for molecular characterization and risk assessment of GMOs		
	Dr. H. Schouten (Wageningen University and Research, The Netherlands)	How mutagenic is <i>Agrobacterium tumefaciens</i> -mediated transformation? Whole genome sequencing of transgenic plants.	
	Dr. E. Van Leeuwe-Kok (RIKILT, The Netherlands)	How to assess the safety of new plant varieties in the years to come?	
	Session discussion		
15:30	Coffee break		
15:45	SESSION III: Novel developments in GM plants		
	Dr. Ir. O. Christiaens (Ghent University, Belgium)	RNAi-based GM crops: Biosafety and risk assessment considerations.	
	Prof. W. Wackernagel (ZKBS, Germany)	ZKBS assessment of two genome edited plants for intended deliberate release in Germany.	
	Session discussion		
17:00	Round table discussion "Challenges for risk assessment/regulation of GMOs"		
	Open discussion introduced by short communications from Dr. K. Pauwels (Scientific Institute of Public Health, Belgium) and Dr. C. van der Vlugt-Bergmans (RIVM, The Netherlands).		
18:00	END DAY 1		
19:30	SOCIAL EVENT: Dinner – Restaurant "Le Labo 4"		

Friday, 24th November 2017

9:00	SESSION IV : GMO medicinal products for human or veterinary use		
	Dr. M. Ramon (EFSA, Italy)	Plasmid vaccines: considerations on the integration potential into the genome and on the risk assessment of non-heritable traits.	
	Dr. F. Lim (Universidad Autonoma de Madrid, Spain)	Risk considerations of the growing biomedical use of herpesvirus vectors.	
	Dr. G.P. Pijlman (Wageningen University, The Netherlands)	Environmental safety of synthetic replicon particle vaccines — risk for RNA recombination with wildtype viruses (RepliSAFE).	
	Session discussion		
11:00	Coffee break		
11:30	SESSION V: Increasing dissemination and use of scientific contributions on GM risk assessment		
	Dr. C. Kohl (Julius Kühn-Institut, Germany)	CADIMA: An open-access online tool and database increasing the transparency and traceability of (GMO) impact data.	
	Dr. I. Munoz Guajardo (EFSA, Italy)	Explanatory note on literature searching conducted in the context of GMO applications.	
	Session discussion		
12:45	Lunch		
14:00	Session VI: Biosafety by design	Biosafety by design	
	Dr. C. van der Vlugt (RIVM, The Netherlands)	Risk Assessment and Management of Gene Drive Technology.	
	Dr. M. Renders (KULeuven, Belgium)	Biosafety: what Xenobiology has to offer.	
	Session discussion		
15:15	KEYNOTE LECTURE		
	Dr. B. Glandorf (RIVM, The Netherlands)	Environmental risk assessment of a potential release of GM mosquitoes on the island of Saba.	
16:15	Concluding remarks		
16:30	CLOSURE OF THE MEETING		